KOLINPHARMA®: new patent in China for Doltendix®
KOLINPHARMA® achieved the first patent in China for Doltendix®.
The total number of
patents obtained thus rises to n. 49, further strengthening our intellectual
property and consolidating our position on the international market.
The patent in China
represents strategical and competitive strengths, which allowed us to defend
and value a product still with still successfully marketed in this dynamical
market.
DOLTENDIX® is a food
supplement based on bioactive peptides from collagen, astaxanthin,
trans-resveratrol and vitamin C, formulated for the well-being of the tendons.
It is the result of an
innovative formulation that demonstrates KOLINPHARMA’s ongoing commitment to
research and develop cutting-edge solutions aimed at the well-being of
consumers.
We are proud to
continue Italian excellence in the nutraceutical sector and to contribute to
improving people’s well-being.
The total number of
patents obtained thus rises to n. 49, further strengthening our intellectual
property and consolidating our position on the international market.
The patent in China
represents strategical and competitive strengths, which allowed us to defend
and value a product still with still successfully marketed in this dynamical
market.
DOLTENDIX® is a food
supplement based on bioactive peptides from collagen, astaxanthin,
trans-resveratrol and vitamin C, formulated for the well-being of the tendons.
It is the result of an
innovative formulation that demonstrates KOLINPHARMA’s ongoing commitment to
research and develop cutting-edge solutions aimed at the well-being of
consumers.
We are proud to
continue Italian excellence in the nutraceutical sector and to contribute to
improving people’s well-being.